StockData
Silence Therapeutics plc logo

Silence Therapeutics plc (SLN) stock

SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.80+0.00 (0.00%)

Close on Nov 17, 2026Market cap $935.48MP/E –Yield –

Silence Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Silence Therapeutics's price to sales ratio was 388.5× on May 29, 2026, against 4.0× a year earlier. Over the last 3 years it ranged from 3.1× to 459.7×, with a median of 12.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026May 29, 2026388.5×+377.3
2025Dec 31, 202511.1×+2.5
2024Dec 31, 20248.6×−20.2
2023Dec 29, 202328.8×–

More Silence Therapeutics figures

See a number that looks wrong?